Solitary Pulmonary Nodule in a Patient with Prior Breast Cancer
A 58-year-old woman with a history of stage II breast cancer treated with lumpectomy, radiation, and tamoxifen 5 years ago presents with an incidental 1.8 cm spiculated right upper lobe nodule found on a chest CT obtained for unrelated abdominal pain. She is asymptomatic. She has a 20 pack-year smoking history, quit 8 years ago. PET/CT is requested to characterize the nodule. Her blood glucose is 168 mg/dL and she ate breakfast 3 hours ago. She has no known diabetes. The nodule's SUVmax on the non-fasting study is 2.1, with background mediastinal blood pool SUVmax of 2.4.
1. How should the fasting glucose and the SUV values be interpreted, and what is the appropriate next step?
Read the worked answer
A glucose of 168 mg/dL exceeds the usual threshold (about 150-200 mg/dL depending on protocol) at which FDG uptake can be suppressed by competitive serum glucose, and the patient was non-fasting, so the study is technically suboptimal. The nodule SUVmax of 2.1 is below mediastinal blood pool (2.4), which is generally considered negative for malignancy, but a spiculated 1.8 cm nodule in a smoker with prior breast cancer carries a high pretest probability. A single low SUV on a non-fasting, hyperglycemic study cannot be used to exclude malignancy. The correct next step is to repeat the PET/CT after an appropriate fast (6+ hours), with glucose rechecked and controlled (ideally <150 mg/dL), and to review the nodule with both SUVmax and visual comparison to mediastinal blood pool and liver. If uptake remains low, tissue diagnosis or close CT surveillance is still warranted given morphology and risk factors.
2. If the repeat fasting study shows SUVmax 3.8 with mediastinal pool 2.2 and liver 2.9, how does that change management, and what confounders must be excluded?
Read the worked answer
An SUVmax of 3.8 exceeding both mediastinal pool and liver background is suspicious for malignancy, and in a spiculated nodule in a former smoker the probability of primary lung cancer is high. Management should move toward tissue diagnosis (CT-guided biopsy or surgical resection depending on staging) rather than observation. Before committing, exclude confounders that inflate FDG uptake: infection or granulomatous disease (endemic fungi, TB), recent biopsy or radiation to the region, and inflammatory conditions; the prior breast radiation field is in the chest and could contribute if the nodule lies within it. Conversely, exclude causes of falsely low uptake such as small size (<1 cm), mucinous histology, or carcinoid. The judgment call is that a positive PET in this context supports but does not replace histology, and the multidisciplinary team should weigh the breast cancer history (possible metastasis) against a new primary lung cancer, since that distinction changes therapy substantially.